Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Net Income (2017 - 2025)

Historic Net Income for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$56.9 million.

  • Sutro Biopharma's Net Income fell 1654.13% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$206.2 million, marking a year-over-year decrease of 6631.12%. This contributed to the annual value of -$227.5 million for FY2024, which is 11301.11% down from last year.
  • Latest data reveals that Sutro Biopharma reported Net Income of -$56.9 million as of Q3 2025, which was down 1654.13% from -$11.5 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Net Income ranged from a high of $31.1 million in Q4 2023 and a low of -$72.5 million during Q4 2024
  • Its 5-year average for Net Income is -$35.9 million, with a median of -$38.5 million in 2023.
  • Its Net Income has fluctuated over the past 5 years, first surged by 18977.57% in 2023, then crashed by 33337.73% in 2024.
  • Sutro Biopharma's Net Income (Quarter) stood at -$38.1 million in 2021, then increased by 9.26% to -$34.6 million in 2022, then surged by 189.78% to $31.1 million in 2023, then tumbled by 333.38% to -$72.5 million in 2024, then grew by 21.55% to -$56.9 million in 2025.
  • Its Net Income was -$56.9 million in Q3 2025, compared to -$11.5 million in Q2 2025 and -$65.3 million in Q1 2025.